Cita APA

WETZLER, M., DONOHUE, K. A., ODENIKE, O. M., FELDMAN, E. J., HURD, D. D., STONE, R. M., . . . LARSON, R. A. (2008). Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107.

Chicago Style Citation

WETZLER, MEIR, KATHLEEN A. DONOHUE, OLATOYOSI M. ODENIKE, ERIC J. FELDMAN, DAVID D. HURD, RICHARD M. STONE, PETER WESTERFELT, CLARA D. BLOOMFIELD, i RICHARD A. LARSON. Feasibility of Administering Oblimersen (G3139; Genasense) With Imatinib Mesylate in Patients With Imatinib Resistant Chronic Myeloid Leukemia – Cancer and Leukemia Group B Study 10107. 2008.

Cita MLA

WETZLER, MEIR, et al. Feasibility of Administering Oblimersen (G3139; Genasense) With Imatinib Mesylate in Patients With Imatinib Resistant Chronic Myeloid Leukemia – Cancer and Leukemia Group B Study 10107. 2008.